

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/GB 02/05730

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K39/395 C07K16/28

A61P7/00

A61P9/00

G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, WPI Data, PAJ, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	M. CICMIL ET AL.: "PECAM-1: a negative regulator of platelet activation?" BLOOD, vol. 96, no. 11 part 1, 16 November 2000 (2000-11-16), page 245A XP001148921 Philadelphia, PA, USA abstract# 1051	1,2,6-9, 11-13
Y	---	3-5, 10, 16, 17
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*8\* document member of the same patent family

Date of the actual completion of the international search

8 May 2003

Date of mailing of the international search report

21/05/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

No01j, F

BEST AVAILABLE COPY

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/Gb J2/05730

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	D. NEWMAN ET AL.: "Inhibition of antigen-receptor signaling by platelet endothelial cell adhesion molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56lck." BLOOD, vol. 97, no. 8, 15 April 2001 (2001-04-15), pages 2351-2357, XP002240194 Philadelphia, PA, USA figures 2,4,6	14,15,18
Y	-----	3-5
X	D. NEWTON-NASH ET AL.: "A new role for platelet-endothelial cell adhesion molecule-1 (CD31): Inhibition of TCR-mediated signal transduction." THE JOURNAL OF IMMUNOLOGY, vol. 163, no. 2, 15 July 1999 (1999-07-15), pages 682-688, XP002240195 Baltimore, MD, USA abstract page 683, right-hand column, line 6 - line 42 figure 2	14,15,18
X	-----	14-16,18
X	P. EVANS ET AL.: "Signaling through CD31 protects endothelial cells from apoptosis." TRANSPLANTATION, vol. 71, no. 3, 15 February 2001 (2001-02-15), pages 457-460, XP008016872 Baltimore, MD, USA abstract page 459, right-hand column, line 9 -page 460, left-hand column, line 9	14-16,18
Y	-----	10,16,17
Y	R. GUMINA ET AL.: "Antibody to platelet/endothelial cell adhesion molecule-1 reduces myocardial infarct size in a rat model of ischemia-reperfusion injury." CIRCULATION, vol. 94, no. 12, 15 December 1996 (1996-12-15), pages 3327-3333, XP008016839 New York, NY, USA abstract	10,16,17

BEST AVAILABLE COPY

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 02/05730

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-9 and 11-13 (all partially, as far as an in vivo method is concerned) and claim 10 (completely) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 14-17 (partially)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

BEST AVAILABLE COPY

## FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 14-17 (partially)

Present claims 14-17 relate to an extremely large number of possible compounds. In fact, the claims contain so many options that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Furthermore, said present claims relate to compounds defined by reference to a desirable characteristic or property, namely an agonist, antagonist or catalytic activity. The claims cover all compounds having these characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely anti-PECAM-1 antibodies as described in the sections 'methods' and 'experimental data' of the description of the present underlying application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.